Tibet Weixinkang pharmaceutical announced that its wholly-owned subsidiary, Yangpu Jingtai Pharmaceutical Co., Ltd., has received the Calcium Gluconate Injection "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, and the pharmaceutical has passed the evaluation of generic drug quality and efficacy consistency.
- Latest
- Detail
卫信康:子公司洋浦京泰葡萄糖酸钙注射液通过仿制药一致性评价
Tibet Weixinkang Pharmaceutical: Subsidiary Yangpu Jingtai Calcium Gluconate Injection has passed the consistency evaluation for generic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Latest
08:26
The global largest silver etf -- iShares Silver Trust has reduced its hold positions by 42.52 tons compared to the previous day, with a current hold position of 14,733.11 tons.
SLV-1.09%
08:17
Follow Hikvision for the latest research trends such as Yi Fangda Zhang Kun and Gao Yi Asset Feng Liu
Hangzhou Hikvision Digital Technology+3.10%
08:14
Yujia Innovation has passed the Hong Kong Stock Exchange hearing, planning to launch PDIE on December 9, with a target transaction size of approximately 70 million US dollars.
HKEX+1.31%
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.